Sunshine Biopharma Inc.
SBFMWNasdaq
$0.03
↓ -13.0%Jul 17 close · end-of-day
Price
1Y↓ -85.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$35.5M
Net Income (TTM)
-$6.0M
Free Cash Flow (TTM)
-$5.9M
Gross Margin
33.0%
Operating Margin
-17.8%
Net Margin
-17.0%
ROE
-28.1%
ROIC
-23.2%
Debt / Equity
—
Net Cash
—
Return 1Y
-83.8%
Company profile
Sunshine Biopharma focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement.
- CEO
- Steve N. Slilaty
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 3
- Headquarters
- Florida
- Website
- sunshinebiopharma.com
Earnings
SBFMW Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$8.1M↓ -9.1%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $71,410.00 | $228,426.00 | $4.3M | $24.1M | $34.9M | $36.3M |
| Gross profit | $45,563.00 | $110,596.00 | $1.7M | $8.3M | $10.7M | $12.3M |
| Operating income | -$576,874.00 | -$2.4M | -$27.0M | -$4.8M | -$5.8M | -$6.2M |
| Net income | -$2.8M | -$12.4M | -$26.7M | -$4.5M | -$5.1M | -$6.0M |
| Diluted EPS | — | -$4.76 | -$1.76 | -$351.36 | -$7.32 | — |
| Operating cash flow | -$657,299.00 | -$1.8M | -$5.2M | -$8.8M | -$12.5M | -$5.3M |
| Free cash flow | -$658,490.00 | -$1.8M | -$5.4M | -$8.9M | -$14.2M | -$5.5M |
| Gross margin | 63.8% | 48.4% | 39.0% | 34.6% | 30.6% | 33.8% |
| Operating margin | -807.8% | -1068.2% | -621.3% | -19.9% | -16.7% | -17.2% |
| Net margin | -3898.7% | -5444.4% | -615.4% | -18.7% | -14.7% | -16.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.3M | $8.4M | $9.6M | $8.9M | $9.4M | $9.4M | $8.6M | $8.1M |
| Gross profit | $2.4M | $2.9M | $3.1M | $2.7M | $3.4M | $3.1M | $3.0M | $2.2M |
| Operating income | -$1.3M | -$1.1M | -$2.1M | -$1.3M | -$2.1M | -$1.1M | -$1.8M | -$1.4M |
| Net income | -$494,300.00 | -$1.2M | -$2.2M | -$1.2M | -$1.8M | -$883,820.00 | -$2.1M | -$1.2M |
| Diluted EPS | -$43.48 | — | — | -$0.44 | -$0.82 | — | — | — |
| Operating cash flow | -$4.6M | -$1.4M | -$3.4M | -$1.7M | -$1.3M | -$727,800.00 | -$1.6M | -$2.1M |
| Free cash flow | -$5.6M | -$1.9M | -$3.5M | -$1.7M | -$1.5M | -$735,840.00 | -$1.6M | -$2.1M |
| Gross margin | 25.3% | 34.0% | 32.2% | 30.7% | 36.4% | 32.6% | 35.3% | 27.0% |
| Operating margin | -13.6% | -13.1% | -21.7% | -14.6% | -21.8% | -11.5% | -20.9% | -17.3% |
| Net margin | -5.3% | -14.2% | -22.5% | -13.3% | -18.8% | -9.4% | -25.0% | -15.4% |
Company news
Jun 25, 2026
Jun 1, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-14 | NATAN DAVID | Award | 100,000 | $0.00 | $0.00 | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.